Completed PHASE4 INTERVENTIONAL 4-arm NCT01801280

Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS

Pharmacokinetic Cross-over Study to Evaluate the Influence of Pantoprazole on MPA Bioavailability Administered as Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium in Maintenance Renal Transplant Patients

Sponsor: Klemens Budde

Conditions Drug Interaction Immunosuppression Transplantation

Interventions Mycophenolate mofetil Mycophenolate sodium Pantoprazole

Updated 7 times since 2017 Last updated: Feb 4, 2019 Started: Jan 31, 2012 Primary completion: Mar 31, 2013 Completion: Mar 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01801280, this PHASE4 trial focuses on Drug Interaction and Immunosuppression and remains completed. Sponsored by Klemens Budde, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Mar 2019 — Jan 2021 [monthly]

Completed PHASE4
Jun 2018 — Mar 2019 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Klemens Budde
Novartis Pharmaceuticals

Data source: Charite University, Berlin, Germany

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany